• Enxing Yu, Erjia Zhang, Xinhuang Lv, Lin Yan, Zhongxiao Lin, Felix Siaw-Debrah, Ying Zhang, Su Yang, Linhui Ruan, Qichuan ZhuGe, and Haoqi Ni.
• Department of Plastic and Reconstructive Surgery, Ningbo First Hospital, Ningbo, Zhejiang, China.
• J. Neurotrauma. 2023 Apr 1; 40 (7-8): 742757742-757.

AbstractAbstract Pyroptosis is considered one of a critical factor in the recovery of neurological function following traumatic brain injury. Brain injury activates a molecular signaling cascade associated with pyroptosis and inflammation, including NLRP3, inflammatory cytokines, caspase-1, gasdermin D (GSDMD), and other pyroptosis-related proteins. In this study, we explored the neuroprotective effects of LDC7559, a GSDMD inhibitor. Briefly, LDC7559, siRNA-GSDMD (si-GSDMD), or equal solvent was administrated to mice with a lipopolysaccharide + nigericin (LPS + Nig) model in vitro or with controlled cortical impact brain injury. The findings revealed that inflammation and pyroptosis levels were decreased by LDC7559 or si-GSDMD treatment both in vitro and in vivo. Immunofluorescence staining, brain water content, hematoxylin and eosin staining, and behavioral investigations suggested that LDC7559 or si-GSDMD inhibited microglial proliferation, ameliorated cerebral edema, reduced brain tissue loss, and promoted brain function recovery. Taken together, LDC7559 may inhibit pyroptosis and reduce inflammation by inhibiting GSDMD, thereby promoting the recovery of neurological function.

19 keywords...

hide…